Syngene International Limited (NSE:SYNGENE)
India · Delayed Price · Currency is INR 703.25
-10.75 (-1.51%)
Aug 1, 2025, 3:29 PM IST
Syngene International Employees
Syngene International had 6,533 employees as of March 31, 2025. The number of employees increased by 23 or 0.35% compared to the previous year.
Employees
6,533
Change (1Y)
23
Growth (1Y)
0.35%
Revenue / Employee
$5,705,189
Profits / Employee
$776,366
Market Cap
279.96B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 6,533 | 23 | 0.35% |
| Mar 31, 2024 | 6,510 | -337 | -4.92% |
| Mar 31, 2023 | 6,847 | 872 | 14.59% |
| Mar 31, 2022 | 5,975 | 538 | 9.90% |
| Mar 31, 2021 | 5,437 | 491 | 9.93% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sun Pharmaceutical Industries | 43,000 |
| Divi's Laboratories | 10,542 |
| Cipla | 30,313 |
| Apollo Hospitals Enterprise | 83,147 |
| Mankind Pharma | 26,978 |
| Zydus Lifesciences | 27,917 |
| Aurobindo Pharma | 26,015 |
| Fortis Healthcare | 12,237 |
Syngene International News
- 8 days ago - Goldman Sachs maintains buy on Syngene, bullish on FY26 early-teens growth outlook, sees 15.5% upside on Q1 beat and rising CRO-led margin gains - Business Upturn
- 9 days ago - Syngene Q1 profit up 59% to Rs 87 crore - The Times of India
- 10 days ago - Syngene International Q1 Results: Revenue grows 11% YoY to Rs 790 crore, Net profit jumps 59% YoY - Business Upturn
- 7 weeks ago - Syngene International receives EIR from USFDA for Biocon Park facility, inspection concludes with VAI classification - Business Upturn
- 3 months ago - Why are Syngene shares down 10% despite Q4 net profit jumping 2.8% YoY? - Business Upturn
- 3 months ago - Syngene International shares hit lower circuit crashing to 10% today after Q4 results - Business Upturn
- 5 months ago - Syngene International shares down 2.50% after USFDA issues Form 483 with five observations - Business Upturn
- 5 months ago - Suven Pharmaceuticals shares surge 12% as Macquarie initiates ‘Outperform’ rating with target price of Rs 1,500, estimating 29.9% upside potential - Business Upturn